Immune responses to the biosimilar infliximab ‘Inflectra’ very closely resemble those to the originator product ‘Remicade’, and consistent clinical outcomes have been obtained from the two products when treating patients with inflammatory bowel disease, international experts have told Australian clinicians. Speaking at a series of meetings hosted by Hospira, a Pfizer Company, Dr Shomron Ben-Horin ...
Infliximab originator and inflectra have similar immune response in IBD: experts
4 Oct 2016
Sponsored by Hospira, a Pfizer company